Interim report for the first half of 2023/24 – Correction
February 05 2024 - 3:45PM
Interim report for the first half of 2023/24 – Correction
ANNOUNCEMENT NO. 250
5 February 2024
Interim report for the first half of
2023/24 – Correction
In connection with the previously published
interim report for the first half of 2023/24 (announcement no.
249), there were errors in the sales and operating results
highlights:
- EBITDA for the
second quarter fell by 36% to DKK 93.1 million, and the EBITDA
margin was 48%, compared with 63% in the year-earlier period.
EBITDA for the first half fell by 36% to DKK 145.2 million, and the
EBITDA margin was 47%, compared with 60% in the year-earlier
period.
The correct is the following:
- EBITDA for the second quarter fell
by 36% to DKK 51.6 million, and the EBITDA margin was 48%, compared
with 63% in the year-earlier period. EBITDA for the first half fell
by 36% to DKK 93.1 million, and the EBITDA margin was 47%, compared
with 60% in the year-earlier period.
The above is also corrected in the attached
interim report for the first half of 2023/24.
Additional information
Rasmus Kofoed, CEO Tel.: (+45) 26 72 68
19
Niels Høy Nielsen, CFO
Tel.: (+45) 25 51 87 24
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets
instruments for cell counting and a wide range of other
measurements. ChemoMetec’s instruments are marketed to the
pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec’s customers include some of the world’s leading
pharmaceutical companies, such as Novartis, Novo Nordisk, H.
Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on
the Nasdaq Copenhagen stock exchange. For more information, go to
www.chemometec.com
Chemometec AS (TG:CHY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chemometec AS (TG:CHY)
Historical Stock Chart
From Jul 2023 to Jul 2024